US Patent 11179364 Licofligozin for the treatment of non-alcoholic steatohepatitis
Patent 11179364 was granted and assigned to Novartis on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+128 characters)
Article
Patent abstract
The disclosure concerns the use of LIK066 in the treatment, prevention or delay of non-alcoholic steatohepatitis.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
C. Daniel Meyers0
Chinweike Ukomadu0
Lloyd Klickstein0
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 24 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111793640
Date of Patent
November 23, 2021
0Patent Application Number
166245270
Date Filed
June 20, 2018
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 25 Nov, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11179364 Licofligozin for the treatment of non-alcoholic steatohepatitis
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11179364
Date of patent
November 23, 2021
Patent application number
16624527
Date Filed
June 20, 2018
Patent primary examiner
Find more entities like US Patent 11179364 Licofligozin for the treatment of non-alcoholic steatohepatitis
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.